Answers are grounded in this paper and cite their sources.
Prophylaxis with oral vancomycin is highly effective in preventing CDI in alloHCT recipients without increasing the risk of graft-versus-host disease or disease relapse. Further evaluation via a prospective study is warranted.
No takes yet. Share an insight, caveat, or question.
Ganetsky et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: